Emerging Therapeutics in Chronic Urticaria.

Chronic urticaria (CU) is a common and long-lasting mast cell-mediated skin disease associated with psychiatric and autoimmune comorbidities, high economic costs, and considerable impact on quality of life. Available therapies show limited efficacy in many CU patients, which may be related to distinct underlying pathophysiology. Targeted and disease-modifying treatments with higher and broader efficacy are needed and are under development for CU. These novel drugs, small molecules, and monoclonal antibodies target mast cells and their receptors, signaling pathways, or mediators and other immune cells. In this article, the authors focus on the most promising emerging therapeutics in advanced development and discuss their potential place in future management of CU. Copyright © 2024 Elsevier Inc. All rights reserved.

Citation

Melba Muñoz, Emek Kocatürk, Marcus Maurer, Pavel Kolkhir. Emerging Therapeutics in Chronic Urticaria. Immunology and allergy clinics of North America. 2024 Aug;44(3):517-528

Mesh Tags

Substances

PMID: 38937013

search → result